The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Seliverstov E.I.

Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Lebedev I.S.

Pirogov Russian National Research Medical University, Moscow, Russia;
Municipal Clinical Hospital No. 1 named after N.I. Pirogov, Moscow, Russia

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

The Anticoagulation Treatment of Venous Thromboembolism: from Randomized Clinical Studies to the Data from the Real Clinical Practice

Authors:

Seliverstov E.I., Lebedev I.S., Leont'ev S.G.

More about the authors

Journal: Journal of Venous Disorders. 2016;10(2): 106‑111

DOI: 10.17116/flebo2016102106-111

Read: 1318 times

Download PDF (RU)
Contact the author
Table of contents

THE ANTICOAGULATION TREATMENT OF VENOUS THROMBOEMBOLISM: FROM RANDOMIZED CLINICAL STUDIES TO THE DATA FROM THE REAL CLINICAL PRACTICE
THE ANTICOAGULATION TREATMENT OF VENOUS THROMBOEMBOLISM: FROM RANDOMIZED CLINICAL STUDIES TO THE DATA FROM THE REAL CLINICAL PRACTICE

To cite this article:

Seliverstov EI, Lebedev IS, Leont'ev SG. The Anticoagulation Treatment of Venous Thromboembolism: from Randomized Clinical Studies to the Data from the Real Clinical Practice. Journal of Venous Disorders. 2016;10(2):106‑111. (In Russ.)
https://doi.org/10.17116/flebo2016102106-111

Подписка 2026 Флебология (Journal of Venous Disorders)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effe­ctiveness of riva­roxaban (Riqulatron) for prevention of venous thro­mboembolic complications in total knee replacement. Piro­gov Russian Journal of Surgery. 2025;(8):55-60
The effe­ctiveness of combined chemotherapy and immu­notherapy, and the search for personalized approaches to treating adva­nced non-small cell lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(4):37-45
Use of fari­cimab in neovascular age-related macu­lar dege­neration and diabetic macu­lar edema in Russia. Resu­lts of the FARWATER retrospective study. Russian Annals of Ophthalmology. 2025;(6):82-91
Expe­rience of Rela­tox (botulinum toxin type A) using for chro­nic migraine treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):134-140
Analysis of the prevalence of musculoskeletal system pathologies among workers of a heavy indu­stry ente­rprise. Russian Journal of Preventive Medi­cine. 2025;(12):52-59
Abstract:

Venous thromboembolism (VTE) is one of the most common cardiovascular problems. Anticoagulation therapy constitutes the mainstay of the treatment and prevention of VTE complications. The advent of new oral anticoagulants (such as rivaroxaban, dabigatran, and apixaban) and their introduction into routine clinical practice provided a powerful tool for the treatment of venous thromboembolism. The study of these new oral anticoagulants in a variety of randomized clinical trials (RCTs) yielded the results comparable with those obtained with the use of standard therapy in terms of the effectiveness and safety of the treatment. At the same time, every fourth patient does not meet the criteria for inclusion in RCTs with the use of oral anticoagulants which emphasizes the importance of observational studies. However, the systematic data of such studies and registries of the patients with venous thromboembolism concerning the application of oral anticoagulants under conditions of real clinical practice have been unavailable until recently. The results of the prospective observational study including the patients with this pathology published in December 2015 confirm the high effectiveness and safety of the new oral anticoagulant rivaroxaban applied under the conditions of real clinical practice.

Keywords:

rivaroxaban
real-life evidence
novel oral anticoagulants

Authors:

Seliverstov E.I.

Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

Lebedev I.S.

Pirogov Russian National Research Medical University, Moscow, Russia;
Municipal Clinical Hospital No. 1 named after N.I. Pirogov, Moscow, Russia

Leont'ev S.G.

Kafedra fakul'tetskoĭ khirurgii im. S.I. Spasokukotskogo Rossiĭskogo gosudarstvennogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Close metadata

References:

  1. Goldhaber S. Pulmonary embolism thromboiysis: A clarion call for international collaboration. Journal of the American College of Cardiology. 1992;19(2):246-247.  doi: 10.1016/0735-1097(92)90473-z.
  2. Spencer F, Emery C, Joffe S, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. Journal of Thrombosis and Thrombolysis. 2009;28(4):401-409.  doi: 10.1007/s11239-009-0378-3.
  3. White R. The Epidemiology of Venous Thromboembolism. Circulation. 2003;107(90231):41-48.  doi: 10.1161/01.cir.0000078468.11849.66.
  4. Cohen A, Agnelli G, Anderson F, et al. Venous thromboembolism in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007. doi: 10.1160/th07-03-0212.
  5. Beckman M, Hooper W, Critchley S, Ortel T.  Venous Thromboembolism. American Journal of Preventive Medicine. 2010;38(4):S495-S501. doi: 10.1016/j.amepre.2009.12.017.
  6. Kearon C. Natural History of Venous Thromboembolism. Circulation. 2003;107(90231):221-230.  doi: 10.1161/01.cir.0000078464.82671.78.
  7. Duru S. State of the art paper Clinical update on pulmonary embolism. Archives of Medical Science. 2014;3:557-565.  doi: 10.5114/aoms.2013.34325.
  8. Kearon C, Akl E, Comerota A, et al. Antithrombotic Therapy for VTE Disease. Chest. 2012;141(2):e419S-e496S. doi: 10.1378/chest.11-2301.
  9. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199-205.  doi: 10.3324/haematol.10516.
  10. Pengo V, Lensing A, Prins M, et al. Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism. New England Journal of Medicine. 2004;350(22):2257-2264. doi: 10.1056/nejmoa032274.
  11. Kahn S. The post-thrombotic syndrome: progress and pitfalls. British Journal of Haematology. 2006;134(4):357-365.  doi: 10.1111/j.1365-2141.2006.06200.x.
  12. Prandoni P.  Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. European Journal of Haematology. 2012;88(3):185-194.  doi: 10.1111/j.1600-0609.2011.01733.x.
  13. Deitelzweig S, Johnson B, Lin J, Schulman K. Prevalence of clinical venous thromboembolism in the USA: Current trends and future projections. Am J Hematol. 2011;86(2):217-220.  doi: 10.1002/ajh.21917.
  14. Kearon C.  A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis. 2012;10(4):507-511.  doi: 10.1111/j.1538-7836.2012.04629.x.
  15. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S.  Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost. 2005;3(5):955-961.  doi: 10.1111/j.1538-7836.2005.01330.x.
  16. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii (2010 g.). Flebologiya. 2010;4:(2):1. (In Russ.).
  17. Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2010;9:CD001100.
  18. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. Journal of Thrombosis and Thrombolysis. 2011;31(3):326-343.  doi: 10.1007/s11239-011-0561-1.
  19. Jorgensen A, FitzGerald R, Oyee J, Pirmohamed M, Williamson P. Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and MetaAnalysis. PLoS ONE. 2012;7(8):e44064. doi: 10.1371/journal.pone.0044064.
  20. Prins M, Lensing A, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013;11(1):21.  doi: 10.1186/1477-9560-11-21.
  21. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine. 2012;366(14):1287-1297. doi: 10.1056/nejmoa1113572.
  22. Dobesh P, Fanikos J. New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities. Drugs. 2014;74(17):2015-2032. doi: 10.1007/s40265-014-0301-x.
  23. Ageno W, Mantovani L, Haas S, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. The Lancet Haematology. 2016;3(1):e12-e21.  doi:10.1016/s2352-3026(15)00257-4.
  24. Bayer Pharma AG: Xarelto® (rivaroxaban) Summary of Product Characteristics Available at: [http:// www. ema. europa. eu/ docs/ en_ GB/ document_ library/ EPAR_ -_ Product_ Information/ human/ 000944/ WC500057108. pdf. Accessed February 2, 2016.
  25. Lyman G. Venous thromboembolism in the patient with cancer. Cancer. 2010;117(7):1334-1349. doi: 10.1002/cncr.25714.
  26. Monreal M, Suaacuterez C, Fajardo J, et al. Management of Patients with Acute Venous Thromboembolism: Findings from the RIETE Registry. Pathophysiology of Haemostasis and Thrombosis. 2003;33(5-6):330-334.  doi: 10.1159/000083823.
  27. Koehler C, Werth S, Tittl L, Beyer-Westendorf J.  Acute treatment of pulmonary embolism with rivaroxaban – real life data from the prospective Dresden NOAC registry (NCT01588119). Blood. 2013;122:2380.
  28. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care — results from the Dresden NOAC registry. British Journal of Clinical Pharmacology. 2014;78(4):908-917.  doi: 10.1111/bcp.12391.
  29. Beyer-Westendorf J, Gelbricht V, Forster K, et al.  Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. European Heart Journal. 2014;35(28):1888-1896. doi: 10.1093/eurheartj/eht557.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.